SEC Form 4 · accession 0001562180-17-000318
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John P. Butler
Officer — CEO and President · Director
Period of report
Jan 19, 2017
Accepted (ET)
Jan 23, 2017 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 19, 2017 | M | 20,000 | $0.47 | A | 373,480 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F3 | $0.47 | Jan 19, 2017 | M | 20,000 | D | — | Sep 16, 2023 | Common Stock | 20,000 | 387,000 | D |
Explanation of responses
- F1This transaction represents the acquisition of common stock as a result of the exercise and hold of derivative securities reported in Table II.
- F2The total amount of beneficial securities includes 1,500 shares of stock purchased on June 30, 2016 at $6.35 per share and 807 shares of stock purchased on December 30, 2016 at $6.48 per shares in connection with the Issuer's Employee Stock Purchase Plan.
- F325% of this option vested on September 16, 2014. The remaining shares vest in equal monthly installments through September 1, 2017.